Skip to main content

Tofacitinib Dosage

Medically reviewed by Drugs.com. Last updated on Sep 11, 2024.

Applies to the following strengths: 11 mg; 22 mg; 5 mg; 10 mg; 1 mg/mL

Usual Adult Dose for Rheumatoid Arthritis

Immediate-release tablets: 5 mg orally twice a day
Extended-release tablets: 11 mg orally once a day

Comments:


Use: For the treatment of patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to at least 1 tumor necrosis factor (TNF) blocker

Usual Adult Dose for Psoriatic Arthritis

Immediate-release tablets: 5 mg orally twice a day
Extended-release tablets: 11 mg orally once a day

Comments:


Use: For the treatment of patients with active PsA who have had an inadequate response or intolerance to at least 1 TNF blocker

Usual Adult Dose for Ankylosing Spondylitis

Immediate-release tablets: 5 mg orally twice a day
Extended-release tablets: 11 mg orally once a day

Comments:


Use: For the treatment of patients with active ankylosing spondylitis who have had an inadequate response or intolerance to at least 1 TNF blocker

Usual Adult Dose for Ulcerative Colitis

Immediate-Release Tablets:


Extended-Release Tablets:

Comments:

Use: For the treatment of patients with moderately to severely active ulcerative colitis who have an inadequate response or intolerance to at least 1 TNF blocker

Usual Pediatric Dose for Juvenile Idiopathic Arthritis

2 Years or Older:
Immediate-release oral solution:


Immediate-release tablets:

Comments:

Use: For the treatment of active polyarticular course juvenile idiopathic arthritis (pcJIA) in patients who have had an inadequate response or intolerance to at least 1 TNF blocker

Renal Dose Adjustments

MILD RENAL DYSFUNCTION: No adjustment recommended.

MODERATE OR SEVERE RENAL DYSFUNCTION:
Patients with RA, PsA, and Ankylosing Spondylitis:


Patients with Ulcerative Colitis:

Patients with pcJIA:

Liver Dose Adjustments

MILD LIVER DYSFUNCTION: No adjustment recommended.

MODERATE LIVER DYSFUNCTION:
Patients with RA, PsA, and Ankylosing Spondylitis:


Patients with Ulcerative Colitis:

Patients with pcJIA:

SEVERE LIVER DYSFUNCTION: Not recommended.

Dose Adjustments

Switching from Immediate-Release Tablets to Extended-Release Tablets:


PATIENTS WITH RA, PsA, AND ANKYLOSING SPONDYLITIS:
Coadministration with strong CYP450 3A4 inhibitors (e.g., ketoconazole), or a moderate CYP450 3A4 inhibitor(s) with a strong CYP450 2C19 inhibitor(s) (e.g., fluconazole):

Lymphocyte count less than 500 cells/mm3, confirmed by repeat testing: Dosing should be discontinued.

Absolute neutrophil count (ANC) 500 to 1000 cells/mm3:

ANC less than 500 cells/mm3: Dosing should be discontinued.

Hemoglobin less than 8 g/dL or a decrease of more than 2 g/dL: Dosing should be interrupted until hemoglobin values have normalized.

PATIENTS WITH ULCERATIVE COLITIS:
Coadministration with strong CYP450 3A4 inhibitors (e.g., ketoconazole), or a moderate CYP450 3A4 inhibitor(s) with a strong CYP450 2C19 inhibitor(s) (e.g., fluconazole):

Lymphocyte count less than 500 cells/mm3, confirmed by repeat testing: Dosing should be discontinued.

ANC 500 to 1000 cells/mm3:

ANC less than 500 cells/mm3: Dosing should be discontinued.

Hemoglobin less than 8 g/dL or a decrease of more than 2 g/dL: Dosing should be interrupted until hemoglobin values have normalized.

PATIENTS WITH pcJIA:
Coadministration with strong CYP450 3A4 inhibitors (e.g., ketoconazole), or a moderate CYP450 3A4 inhibitor(s) with a strong CYP450 2C19 inhibitor(s) (e.g., fluconazole):

Lymphocyte count less than 500 cells/mm3, confirmed by repeat testing: Dosing should be discontinued.

ANC 500 to 1000 cells/mm3: Dosing should be interrupted until ANC is greater than 1000 cells/mm3.

ANC less than 500 cells/mm3: Dosing should be discontinued.

Hemoglobin less than 8 g/dL or a decrease of more than 2 g/dL: Dosing should be interrupted until hemoglobin values have normalized.

Precautions

US BOXED WARNINGS:


CONTRAINDICATIONS: None

Safety and efficacy have not been established in pcJIA patients younger than 2 years. Safety and efficacy of the extended-release formulation or for indications other than pcJIA have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

HEMODIALYSIS:
Patients with RA, PsA, and Ankylosing Spondylitis:


Patients with Ulcerative Colitis:

Patients with pcJIA:

Comments:

Other Comments

Administration advice:


Storage requirements:

Monitoring:

Patient advice:

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.